To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification: Transactions by persons discharging managerial responsibilities & persons closely associated with them

Release Date: 25/05/2023 15:00
Code(s): MEI     PDF:  
Wrap Text
Notification: Transactions by persons discharging managerial responsibilities & persons closely associated with them

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)

25 May 2023

         NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
            RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM

 Vesting of awards under the Company's Short-Term Incentive (‘STI’) scheme and Long-Term
                                 Incentive Plan (‘LTIP’)

In connection with the recommended cash acquisition of Mediclinic by Manta Bidco Limited (a newly
formed company owned by: (i) Remgro Limited and certain of its subsidiaries; and (ii) SAS Shipping
Agencies Services S.à r.l., a wholly owned subsidiary of MSC Mediterranean Shipping Company SA)
(the ‘Acquisition’), this notification sets out the details of the vesting of awards over ordinary shares in
Mediclinic granted under the Company’s STI and LTIP to Directors and other persons discharging
managerial responsibilities (‘PDMRs’) in the financial years ended on 31 March 2020, 31 March 2021,
31 March 2022 and 31 March 2023.

The awards vested on 24 May 2023 and will be settled in cash, based on the offer price to be paid by
Manta Bidco Limited in connection with the Acquisition, being 501 pence per share.

The notifications that follow are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.

1.   Details of PDMR / person closely associated with them
a)   Name                   Dr Carel Aron van der Merwe

2.   Reason for the notification
a)   Position / status      Group Chief Executive Officer – Mediclinic International plc
b)   Initial notification / Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                   Mediclinic International plc
b)   LEI                    2138002S5BSBIZTD5I60

4.1  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted

a)   Description of the     Ordinary Shares
     financial instrument
     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 19 June 2019;
                            2. 14 December 2020;
                            3. 4 June 2021; and
                            4. 5 August 2022.

                            Vesting of deferred awards over ordinary shares in Mediclinic
                            granted at nil cost under the Company’s STI on:

                            5. 4 June 2021; and
                            6. 5 August 2022

c)   Price(s) and
     volume(s)                            Price(s)               Volume(s)
                             1.           £nil                      45 185
                             2.           £nil                     176 093
                             3.           £nil                     118 727
                             4.           £nil                      49 524
                             5.           £nil                    122 614
                             6.           £nil                      74 718

d)   Aggregated
     information
     Aggregated volume      586 861
     Price                  £nil

e)   Date of the            24 May 2023
     transaction

f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Petrus Jurgens Myburgh

2.   Reason for the notification
a)   Position / status      Group Chief Financial Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                   Mediclinic International plc
b)   LEI                    2138002S5BSBIZTD5I60

4.1  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted

a)   Description of the     Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 19 June 2019;
                            2. 14 December 2020;
                            3. 4 June 2021; and
                            4. 5 August 2022.

                            Vesting of deferred awards over ordinary shares in Mediclinic
                            granted at nil cost under the Company’s STI on:

                            5. 4 June 2021; and
                            6. 5 August 2022
c)   Price(s) and
     volume(s)                          Price(s)              Volume(s)
                            1.          £nil                     24 981
                            2.          £nil                     97 549
                            3.          £nil                     63 523
                            4.          £nil                     30 900
                            5.          £nil                     80 655
                            6.          £nil                     47 488

d)   Aggregated
     information

     Aggregated volume      345 096

     Price                  £nil

e)   Date of the            24 May 2023
     transaction
f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Gert Cornelis Hattingh

2.   Reason for the notification
a)   Position / status        Group Chief Governance Officer – Mediclinic International plc
b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument
     Identification Code     GB00B8HX8Z88

b)   Nature of the           Vesting of conditional awards over ordinary shares in Mediclinic
     transaction             granted at nil cost under the Company’s LTIP on:

                             1. 14 December 2020;
                             2. 4 June 2021; and
                             3. 5 August 2022.
c)   Price(s) and
     volume(s)                            Price(s)               Volume(s)
                             1.           £nil                      37 839
                             2.           £nil                      24 331
                             3.           £nil                       5 983

d)   Aggregated
     information

     Aggregated volume        68 153

     Price                    £nil

e)   Date of the              24 May 2023
     transaction
f)   Place of the             Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                     Dr Dirk Cornelius le Roux

2.   Reason for the notification
a)   Position / status        Group Chief Information Officer – Mediclinic International plc

b)   Initial notification /   Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                    2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.
c)   Price(s) and
     volume(s)                          Price(s)                Volume(s)
                            1.          £nil                       29 654
                            2.          £nil                       19 053
                            3.          £nil                        4 677
d)   Aggregated
     information

     Aggregated volume      53 384

     Price                  £nil

e)   Date of the            24 May 2023
     transaction

f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Dr Daniel Liedtke

2.   Reason for the notification
a)   Position / status      Chief Executive Officer: Hirslanden
b)   Initial notification / Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                   Mediclinic International plc
b)   LEI                    2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.
c)   Price(s) and
     volume(s)                          Price(s)               Volume(s)
                            1.          £nil                      70 352
                            2.          £nil                      39 423
                            3.          £nil                      10 849

d)   Aggregated
     information

     Aggregated volume      120 624

     Price                  £nil

e)   Date of the            24 May 2023
     transaction
f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Magnus Oetiker

2.   Reason for the notification
a)   Position / status      Group Chief Strategy Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.
c)   Price(s) and
     volume(s)                          Price(s)              Volume(s)
                            1.          £nil                     56 587
                            2.          £nil                     32 303
                            3.          £nil                     10 822
d)   Aggregated
     information

     Aggregated volume      99 712

     Price                  £nil

e)   Date of the            24 May 2023
     transaction
f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Koert Hendrik Stefanus Pretorius

2.   Reason for the notification
a)   Position / status      Group Chief Operating Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the     Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88

b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.

c)   Price(s) and
     volume(s)                         Price(s)                Volume(s)
                            1.         £nil                       39 509
                            2.         £nil                       25 469
                            3.         £nil                        6 261
d)   Aggregated
     information

     Aggregated volume      71 239

     Price                  £nil

e)   Date of the            24 May 2023
     transaction
f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Dr René Toua

2.   Reason for the notification
a)   Position / status      Group Chief Clinical Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88
b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.
c)   Price(s) and
     volume(s)                         Price(s)                Volume(s)
                            1.         £nil                       30 301
                            2.         £nil                       19 829
                            3.         £nil                        4 915
d)   Aggregated
     information

     Aggregated volume      55 045

     Price                  £nil

e)   Date of the            24 May 2023
     transaction

f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Dr Tyson Bruno Welzel

2.   Reason for the notification
a)   Position / status      Group Chief Innovation Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88
b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            1. 14 December 2020;
                            2. 4 June 2021; and
                            3. 5 August 2022.

c)   Price(s) and
     volume(s)                         Price(s)               Volume(s)
                            1.         £nil                      24 080
                            2.         £nil                      15 896
                            3.         £nil                       8 460
d)   Aggregated
     information

     Aggregated volume      48 436

     Price                  £nil

e)   Date of the            24 May 2023
     transaction
f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Hein van Eck

2.   Reason for the notification
a)   Position / status      Chief Executive Officer – Mediclinic Middle East

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code    GB00B8HX8Z88
b)   Nature of the          Vesting of conditional awards over ordinary shares in Mediclinic
     transaction            granted at nil cost under the Company’s LTIP on:

                            4. 14 December 2020;
                            5. 4 June 2021; and
                            6. 5 August 2022.
c)   Price(s) and
     volume(s)                         Price(s)               Volume(s)
                            4.         £nil                       8 833
                            5.         £nil                       5 011
                            6.         £nil                       2 102
d)   Aggregated
     information

     Aggregated volume      15 946

     Price                  £nil

e)   Date of the            24 May 2023
     transaction

f)   Place of the           Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them
a)   Name                   Greg van Wyk

2.   Reason for the notification
a)   Position / status      Chief Executive Officer: Mediclinic Southern Africa

b)   Initial notification /  Initial Notification
     amendment

3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc
b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88
b)   Nature of the           Vesting of conditional awards over ordinary shares in Mediclinic
     transaction             granted at nil cost under the Company’s LTIP on:

                             1. 14 December 2020;
                             2. 4 June 2021; and
                             3. 5 August 2022.

c)   Price(s) and
     volume(s)                      Price(s)                 Volume(s)
                             4.     £nil                        22 919
                             5.     £nil                        14 800
                             6.     £nil                         5 681
d)   Aggregated
     information
     Aggregated volume       43 400
     Price                   £nil

e)   Date of the             24 May 2023
     transaction

f)   Place of the            Outside a trading venue
     transaction

CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 25-05-2023 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story